A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Trial Profile

A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2017

At a glance

  • Drugs Elagolix (Primary) ; Estradiol/norethisterone
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 09 May 2017 Results for cohort 1 (n=259), presented at the 65th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
    • 09 May 2017 Acoording to a Neurocrine Biosciences media release, positive efficacy data was presented at the Congress of the Society of Endometriosis and Uterine Disorders (SEUD) in Singapore 2017.
    • 07 Apr 2017 According to an AbbVie media release, results from the 600mg cohort were similar and will be reported in a future publication.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top